News
Published Data as of
In the SURMOUNT-ADOLESCENTS trial in teens with obesity, tirzepatide reduced body mass index (BMI) by 18.5% at week 72. Placebo led to a 0.5% increase.1 JAMA published the trial on November 15, 2026.2 In the trial, 79.6% of teens on tirzepatide reached at least a 5% BMI reduction, versus 28.5% on placebo.1,2 Serious adverse events occurred in 7.4% of the tirzepatide group and 3.9% of the placebo group.1
In the trial, teens on tirzepatide saw their BMI fall by 18.5% at week 72. Teens on placebo saw a 0.5% increase.1 In the trial, tirzepatide plus a healthy lifestyle intervention led to significant reductions in percent change in BMI compared with placebo at 72 weeks.5
At week 72, 87 of 109 teens on tirzepatide reached at least a 5% BMI reduction, compared with 14 of 51 on placebo.2 The risk difference between the two groups in the trial was 51.2 percentage points.1 All 10 key secondary outcomes in the trial favored tirzepatide.2
| Measure | Tirzepatide | Placebo |
|---|---|---|
| Change in BMI at week 72 in the trial | 18.5% reduction in the trial | 0.5% increase in the trial1 |
| At least 5% BMI reduction in the trial | 79.6% of teens in the trial | 28.5% of teens in the trial1,2 |
| Teens in the trial with at least 5% BMI reduction | 87 of 109 teens in the trial | 14 of 51 teens in the trial2 |
The trial randomized 160 adolescents with obesity or overweight with obesity-related complications to tirzepatide or placebo.1,5 Of these, 109 were randomized to tirzepatide and 51 to placebo.1 Researchers gave tirzepatide in addition to a healthy lifestyle intervention and compared BMI change at 72 weeks.5
The results were presented at the Obesity Society's ObesityWeek 2026 in Washington, DC, on November 15, 2026.1 JAMA published the trial online the same day.1,2
In a trial in adults with obesity without diabetes, tirzepatide reduced body weight at week 72 by 15%, 19.5% and 20.9%. Placebo reduced it by 3.1%.6 In a trial in people with type 2 diabetes and heart disease, tirzepatide compared with dulaglutide was noninferior for the primary composite end point.7 In the same group of patients, tirzepatide lowered the risk of the primary composite kidney outcome by 23% versus dulaglutide.8
The FDA approved Zepbound in 2023 to reduce and maintain body weight in adults with obesity.4 The FDA approved Mounjaro in 2022. Its FDA label covers glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes.9 The EMA approved Mounjaro in the EU in 2022.10
For long-term treatment of obesity in adolescents, the FDA has approved orlistat, liraglutide, semaglutide and phentermine-topiramate.1
As of November 15, 2026, PepBank holds 378 tirzepatide studies where tirzepatide was given.3 Those studies give PepBank 2165 results for tirzepatide.3
The FDA approved Zepbound in 2023 to reduce and maintain body weight in adults with obesity, or overweight with at least one weight-related condition.4 The FDA approved Mounjaro in 2022. Its FDA label covers glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes.9 For adolescents with obesity, the FDA has approved orlistat, liraglutide, semaglutide and phentermine-topiramate.1
The SURMOUNT-ADOLESCENTS trial randomized 160 participants. Of these, 109 were randomized to tirzepatide and 51 to placebo.1 The trial ran in adolescents with obesity or overweight with obesity-related complications. Researchers gave tirzepatide in addition to a healthy lifestyle intervention.5 At week 72 in the trial, 87 of 109 teens on tirzepatide reached at least a 5% BMI reduction. On placebo, 14 of 51 teens reached it.2
JAMA published the SURMOUNT-ADOLESCENTS trial online on November 15, 2026.2 The results were presented the same day at the Obesity Society's ObesityWeek 2026 in Washington, DC.1,2 JAMA Network said it was publishing two clinical trials and its fourth JAMA Summit Report at ObesityWeek.5
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated